SecBot SecBot
Biotech Drug Report Generated Jul 13, 2026

CYTOGAM

KMDA·KAMADA LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already FDA-approved and commercially marketed
Why 4/10
CYTOGAM is already FDA-approved and marketed with no pending regulatory decision or pivotal readout within the next ~12 months. The SHIELD post-marketing study (NCT07009548) has a primary completion date of December 2027. The ISHLT data presentation in July 2026 was a routine scientific communication, not a binary catalyst. ImpactScore 4 reflects a mature commercial product with steady but non-catalytic growth.
Actionable Insight NEUTRAL

CYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.

Price Chart

Loading chart...

Executive Summary

CYTOGAM is an FDA-approved, commercially marketed intravenous hyperimmune globulin used to prevent cytomegalovirus disease in solid organ transplant recipients. It is the sole FDA-approved CMV hyperimmune globulin for this indication. Kamada acquired the product from CSL Behring in 2021 and now manufactures it in-house (FDA-approved 2023). CYTOGAM generated ~$22.5M in revenue for Kamada in 2024 (~12-13% of total revenue), growing 31% year-over-year. The drug has no imminent binary catalyst, the SHIELD post-marketing study won't read out before 2028, and the recent ISHLT data presentation was supportive but routine. Kamada's stock is more meaningfully driven by its larger products (KEDRAB rabies IG at ~$50M, Glassia alpha-1 at a larger share) and overall 2026 revenue guidance of $200-205M.

How It Works

CYTOGAM is a purified blood product (hyperimmune globulin) rich in antibodies that specifically neutralize cytomegalovirus (CMV). It is injected intravenously into transplant patients to help prevent CMV infection, working outside the body's cells by neutralizing the virus before it can infect cells. It is typically used alongside standard antiviral drugs (like valganciclovir or ganciclovir) that work inside the cells, providing complementary, dual-mode protection.

Trial Status

CYTOGAM has been FDA-approved since the 1990s (originally by CSL Behring/MedImmune). Kamada acquired it in November 2021 and received FDA approval to manufacture it at its own Israel facility in May 2023. A post-marketing investigator-initiated study (SHIELD, NCT07009548) enrolled its first patient in November 2025, testing CYTOGAM to prevent late CMV in high-risk kidney transplant recipients, with primary completion estimated December 2027. Additional retrospective lung-transplant data from 324 patients was presented at the ISHLT 2026 annual meeting in Toronto (July 2026), showing CMV high-risk recipients not receiving CMVIG had worse outcomes.

The Two-Sided Case

▲ Bull Case5
Sole FDA-approved CMV hyperimmune globulin for transplant, no direct approved competitor in the US market, giving Kamada an effective monopoly in this niche
Revenue growing strongly: CYTOGAM sales reached $22.5M in 2024, up 31% YoY (per Kamada's 2024 annual results)
Kamada received FDA approval to manufacture CYTOGAM in-house (May 2023), improving vertical integration and margins at the Beit Kama facility
Supporting clinical data is accumulating, ISHLT 2026 retrospective data on 324 lung-transplant patients showed worse outcomes for high-risk patients not receiving CMVIG, which could drive increased utilization
Kamada is investing in a post-marketing research program (SHIELD study and KOL engagement) to strengthen the evidence base and expand use
▼ Bear Case5
Small contributor to Kamada's overall business: CYTOGAM's ~$22.5M is only ~12-13% of total 2024 revenue of $180.5M, making it a minority driver of the stock
No near-term binary catalyst, SHIELD study primary completion is December 2027, no upcoming PDUFA or pivotal readout within 12 months
Competition from standard-of-care oral antivirals (valganciclovir/ganciclovir) is well-established, and CYTOGAM is an adjunctive add-on, not a standalone replacement
Retrospective ISHLT data is supportive but low-tier evidence; prospective RCT data from SHIELD won't arrive for years
Plasma-derived product exposes Kamada to plasma-supply chain risk and manufacturing complexity

Upcoming Catalysts

  • Q2 2026 earnings call (~August 12, 2026), CYTOGAM sales update and full-year 2026 guidance tracking
  • Full publication of ISHLT 2026 retrospective lung-transplant data expected later in 2026
  • SHIELD study (NCT07009548) enrollment updates, but primary completion not until December 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

KAMADA LTD 6-K KMDA ·Originating report

Sources · 13

Hover a chip for the title
1 cytogam.com2 fda.gov3 kamada.com4 kamada.com5 biospace.com6 globenewswire.com7 biospace.com8 stocktitan.net9 kamada.com10 clinicaltrials.gov11 fda.gov12 sec.gov13 sec.gov